Deepak R Rao

Array ( [id] => 18628577 [patent_doc_number] => 20230287449 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTION [patent_app_type] => utility [patent_app_number] => 17/049061 [patent_app_country] => US [patent_app_date] => 2019-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7822 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17049061 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16569038 [patent_doc_number] => 20210008044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => PREVENTION OR TREATMENT OF CHRONIC ORGAN INJURY [patent_app_type] => utility [patent_app_number] => 17/042027 [patent_app_country] => US [patent_app_date] => 2019-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32667 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17042027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16778341 [patent_doc_number] => 20210115419 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => CRISPR/Cas9-Mediated Exon-Skipping Approach for USH2A-Associated Usher Syndrome [patent_app_type] => utility [patent_app_number] => 17/040629 [patent_app_country] => US [patent_app_date] => 2019-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14289 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17040629 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16555758 [patent_doc_number] => 20210000906 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => MODULATION OF HSD17B13 EXPRESSION [patent_app_type] => utility [patent_app_number] => 16/982733 [patent_app_country] => US [patent_app_date] => 2019-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29168 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -68 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16982733 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17050772 [patent_doc_number] => 20210260206 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => CHIMERIC PEPTIDES FOR ANTISENSE DELIVER [patent_app_type] => utility [patent_app_number] => 16/981145 [patent_app_country] => US [patent_app_date] => 2019-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13602 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16981145 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16571028 [patent_doc_number] => 20210010034 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => TRANSIENT CELLULAR REPROGRAMMING FOR REVERSAL OF CELL AGING [patent_app_type] => utility [patent_app_number] => 16/979842 [patent_app_country] => US [patent_app_date] => 2019-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22009 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16979842 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16541307 [patent_doc_number] => 20200407720 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => A DBAIT MOLECULE AGAINST ACQUIRED RESISTANCE IN THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/979892 [patent_app_country] => US [patent_app_date] => 2019-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12185 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16979892 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16671289 [patent_doc_number] => 20210060052 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => IN SITU METHODS OF INDUCING OF IMMUNE RESPONSE [patent_app_type] => utility [patent_app_number] => 16/981052 [patent_app_country] => US [patent_app_date] => 2019-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25526 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16981052 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16598397 [patent_doc_number] => 20210024928 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => C/EBP ALPHA SARNA COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/970090 [patent_app_country] => US [patent_app_date] => 2019-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15013 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16970090 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16762366 [patent_doc_number] => 20210107947 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => MODIFIED VIRAL CAPSIDS [patent_app_type] => utility [patent_app_number] => 16/970004 [patent_app_country] => US [patent_app_date] => 2019-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26720 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16970004 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16612146 [patent_doc_number] => 20210030799 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => TUMOR ENVIRONMENT-SPECIFIC EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS [patent_app_type] => utility [patent_app_number] => 16/968861 [patent_app_country] => US [patent_app_date] => 2019-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11576 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16968861 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16712246 [patent_doc_number] => 20210079393 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => ANTISENSE OLIGONUCLEOTIDES FOR RNA EDITING [patent_app_type] => utility [patent_app_number] => 16/970193 [patent_app_country] => US [patent_app_date] => 2019-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16060 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 168 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16970193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16932783 [patent_doc_number] => 20210198672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-01 [patent_title] => APTAMER FOR SCLEROSTIN AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/969314 [patent_app_country] => US [patent_app_date] => 2019-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11631 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16969314 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16391348 [patent_doc_number] => 20200332289 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => GAPMER OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE [patent_app_type] => utility [patent_app_number] => 15/733306 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46890 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -65 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15733306 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16343938 [patent_doc_number] => 20200308588 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => HIGH MOBILITY GROUP BOX-1 (HMGB1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/954625 [patent_app_country] => US [patent_app_date] => 2018-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61140 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -85 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16954625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16374338 [patent_doc_number] => 20200323180 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => METHODS FOR THE PRODUCTION OF STERILE FISH AND OTHER EGG-PRODUCING AQUATIC ANIMALS AND COMPOUNDS FOR USE IN THE METHODS [patent_app_type] => utility [patent_app_number] => 16/771940 [patent_app_country] => US [patent_app_date] => 2018-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10953 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16771940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16870466 [patent_doc_number] => 20210163933 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => ARC PROTEIN EXTRACELLULAR VESICLE NUCLEIC ACID DELIVERY PLATFORM [patent_app_type] => utility [patent_app_number] => 16/770834 [patent_app_country] => US [patent_app_date] => 2018-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17255 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16770834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16511474 [patent_doc_number] => 20200390731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => MANIPULATION OF THE RETINOIC ACID SIGNALING PATHWAY [patent_app_type] => utility [patent_app_number] => 16/763180 [patent_app_country] => US [patent_app_date] => 2018-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71937 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16763180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16177226 [patent_doc_number] => 20200224194 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => EXPRESSION SYSTEMS THAT FACILITATE NUCLEIC ACID DELIVERY AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/649105 [patent_app_country] => US [patent_app_date] => 2018-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37306 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16649105 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16484285 [patent_doc_number] => 20200377886 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY [patent_app_type] => utility [patent_app_number] => 16/647728 [patent_app_country] => US [patent_app_date] => 2018-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34483 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16647728 [rel_patent_id] =>[rel_patent_doc_number] =>)